Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $110
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Citizens analyst Jason N. Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and raises the price target from $105 to $110.
Citizens analyst Jason N. Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and raises the price target from $105 to $110.